Optima Medical Innovations Corp. (TOKIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Optima Medical Innovations Corp. (TOKIF) trades at $0.01. Optima Medical Innovations Corp. focuses on producing and selling hemp-based cannabidiol (CBD) products and operating multidisciplinary pain clinics. Market cap: $101.43M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for TOKIF: TOKIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TOKIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TOKIF: 1/1 perspectives are bearish.
How is this calculated? →Optima Medical Innovations Corp. (TOKIF) Healthcare & Pipeline Overview
Optima Medical Innovations Corp. operates in the healthcare sector, focusing on hemp-based CBD products and pain management clinics. The company offers a diversified product line and services, including CBD oils, capsules, topicals, and comprehensive pain treatments, primarily in Canada and internationally, positioning itself in the growing cannabis and pain management market.
What Is the Investment Thesis for TOKIF?
Optima Medical Innovations Corp. presents a speculative investment opportunity within the cannabis and pain management sectors. The company's diverse revenue streams, including CBD product sales and clinic operations, offer potential growth avenues. However, the company's negative profit margin of -85.9% raises concerns about its financial sustainability. The company's research agreement with Ryerson University could lead to the development of novel products, acting as a potential catalyst. The stock's negative beta of -0.26 suggests it is less volatile than the market. Investors should carefully consider the risks associated with OTC-listed companies and the competitive landscape of the CBD market before investing.
Based on FMP financials and quantitative analysis
TOKIF Key Highlights
- Market Cap of $101.43M indicates the company's small size within the healthcare sector.
- Negative P/E ratio of -0.35 reflects the company's current lack of profitability.
- Gross Margin of 29.9% suggests potential for improvement in operational efficiency.
- Negative Profit Margin of -85.9% highlights significant challenges in achieving profitability.
- The company's research agreement with Ryerson University signals a commitment to innovation and product development in the medical cannabis field.
Who Are TOKIF's Competitors?
TOKIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127.35M | 53 |
| GRUSF Grown Rogue International Inc. | $0.47 | +2.35% | $117.67M | 43 |
| LDXHF Lumos Diagnostics Holdings Limited | $0.08 | +0.00% | $61.07M | 40 |
| MSCLF Satellos Bioscience Inc. | $6.25 | +11.81% | $96.62M | 52 |
| ORXOF Orexo AB (publ) | $2.90 | +38.10% | $101.87M | 50 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TOKIF's Key Strengths?
- Diverse product and service offerings (CBD products and pain clinics).
- Research partnership with Ryerson University for product development.
- Presence in both the CBD and pain management markets.
- International sales channels.
What Are TOKIF's Weaknesses?
- Negative profit margin (-85.9%).
- Small market capitalization ($0.10B).
- Reliance on the evolving regulatory landscape of the cannabis industry.
- OTC market listing may limit investor access and liquidity.
What Could Drive TOKIF Stock Higher?
- Potential regulatory changes in the cannabis industry could create new market opportunities.
- Results from the research agreement with Ryerson University could lead to new product development.
- Expansion of the company's CBD product line and geographic reach.
- Increasing consumer awareness and acceptance of CBD products.
- Growth in the pain management market due to an aging population.
What Are the Key Risks for TOKIF?
- Negative return on equity (-83.4%) — the business is not currently generating profit on shareholder capital.
- Negative profit margin and financial instability.
- Intense competition from established pharmaceutical companies and other cannabis producers.
- Changing regulations and legal restrictions on cannabis products.
- Adverse health effects or negative publicity related to CBD use.
- Limited liquidity and transparency due to OTC listing.
What Are the Growth Opportunities for TOKIF?
- Expansion of CBD Product Line: Optima Medical Innovations Corp. can expand its CBD product line to include new formulations, delivery methods, and targeted health applications. The global CBD market is projected to reach $20 billion by 2025, offering significant growth potential. By investing in research and development, the company can create differentiated products that cater to specific consumer needs and preferences, increasing market share and revenue.
- Geographic Expansion: The company can expand its operations into new geographic markets, both within Canada and internationally. The European CBD market is particularly attractive, with increasing regulatory acceptance and consumer demand. By establishing partnerships with local distributors and retailers, Optima Medical Innovations Corp. can efficiently enter new markets and capitalize on the growing global demand for CBD products.
- Strategic Partnerships: Optima Medical Innovations Corp. can form strategic partnerships with other companies in the healthcare and wellness sectors. Collaborating with established healthcare providers, fitness centers, and wellness clinics can provide access to new customer channels and enhance brand credibility. These partnerships can also facilitate the development of integrated health solutions that combine CBD products with other therapies and services.
- Development of Medical-Grade Products: The company's research agreement with Ryerson University provides an opportunity to develop new medical-grade cannabis products. By focusing on clinically validated formulations and targeted therapeutic applications, Optima Medical Innovations Corp. can differentiate itself from competitors and capture a share of the growing medical cannabis market. Successful development and commercialization of these products could significantly increase revenue and profitability.
- Telemedicine and Virtual Care: Optima Medical Innovations Corp. can leverage telemedicine and virtual care technologies to expand access to its pain management services. By offering virtual consultations, remote monitoring, and online therapy programs, the company can reach patients in remote areas and improve convenience for existing patients. This approach can also reduce overhead costs and increase the scalability of the company's pain management business.
What Opportunities Does TOKIF Have?
- Expansion into new geographic markets.
- Development of new medical-grade cannabis products.
- Strategic partnerships with healthcare providers.
- Increased consumer awareness and acceptance of CBD products.
What Threats Does TOKIF Face?
- Intense competition from established pharmaceutical companies and other cannabis producers.
- Changing regulations and legal restrictions on cannabis products.
- Potential for adverse health effects or negative publicity related to CBD use.
- Economic downturns could reduce consumer spending on non-essential healthcare products and services.
What Are TOKIF's Competitive Advantages?
- Proprietary formulations and delivery methods for CBD products.
- Established network of multidisciplinary pain clinics.
- Research agreement with Ryerson University for innovative product development.
- Brand recognition and reputation in the Canadian market.
What Does TOKIF Do?
Optima Medical Innovations Corp., formerly known as Tree of Knowledge International Corp., was rebranded in November 2021. The company is based in Toronto, Canada, and operates in the healthcare sector, specializing in the production and sale of hemp-based cannabidiol (CBD) products and the operation of multidisciplinary pain clinics. Its product line includes industrial hemp-derived CBD oil, airless metered pens, capsules, topicals, and tinctures. These products are marketed and sold both in Canada and internationally. In addition to its CBD product offerings, Optima Medical Innovations Corp. operates multidisciplinary pain clinics. These clinics provide a range of services focused on the treatment of chronic pain, including comprehensive medical and interventional pain management, independent medical evaluations, physiotherapy and chiropractic care, medical cannabis, and platelet-rich plasma therapy, as well as mindfulness teaching. The company also has a research agreement with Ryerson University for medical cannabis research and the development of new medical-grade products, highlighting its commitment to innovation and scientific advancement in the field.
What Products and Services Does TOKIF Offer?
- Produces and sells hemp-based cannabidiol (CBD) products.
- Offers industrial hemp-derived CBD oil.
- Provides airless metered pens, capsules, topicals, and tinctures.
- Operates multidisciplinary pain clinics.
- Focuses on the treatment of chronic pain.
- Offers comprehensive medical and interventional pain management.
- Provides independent medical evaluations, physiotherapy, and chiropractic care.
- Offers medical cannabis and platelet-rich plasma therapy, as well as mindfulness teaching.
How Does TOKIF Make Money?
- Sales of hemp-based CBD products through various channels.
- Revenue generation from multidisciplinary pain clinics offering various treatments.
- Partnerships with research institutions for new product development.
- Expansion into new geographic markets to increase customer base.
What Industry Does TOKIF Operate In?
Optima Medical Innovations Corp. operates within the rapidly evolving cannabis and pain management industries. The global CBD market is experiencing substantial growth, driven by increasing consumer awareness and acceptance of CBD products for various health and wellness applications. The pain management market is also expanding, fueled by an aging population and the rising prevalence of chronic pain conditions. Optima Medical Innovations Corp. faces competition from established pharmaceutical companies, other cannabis producers, and specialized pain clinics. Companies like CORBF, GRUSF, LDXHF, MSCLF, and ORXOF represent key competitors in these overlapping markets.
Who Are TOKIF's Key Customers?
- Individuals seeking pain relief and alternative therapies.
- Consumers interested in hemp-based CBD products for wellness.
- Patients requiring comprehensive pain management services.
- Healthcare providers seeking partnerships for pain management solutions.
How Optima Medical Innovations Corp. Is Valued
Optima Medical Innovations Corp. carries a market capitalization of $101.43M, placing it in the micro-cap category.
Company Profile
Optima Medical Innovations Corp. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Ali Sakhavati. TOKIF has traded publicly since 2018.
ROE -83%Key Financial Metrics
Return on equity for Optima Medical Innovations Corp. stands at -83.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -54.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
Optima Medical Innovations Corp.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.43 places it in the safe zone, indicating low near-term bankruptcy risk.
TOKIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse product and service offerings (CBD products and pain clinics).
- Research partnership with Ryerson University for product development.
- Presence in both the CBD and pain management markets.
- International sales channels.
Bear Case
- Negative profit margin (-85.9%).
- Small market capitalization ($0.10B).
- Reliance on the evolving regulatory landscape of the cannabis industry.
- OTC market listing may limit investor access and liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TOKIF Latest News
No recent news available for TOKIF.
TOKIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TOKIF.
Price Targets
Wall Street price target analysis for TOKIF.
TOKIF MoonshotScore
What does this score mean?
The MoonshotScore rates TOKIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ali Sakhavati
CEO
Ali Sakhavati serves as the CEO of Optima Medical Innovations Corp. His background includes experience in the healthcare and pharmaceutical sectors, with a focus on business development and strategic partnerships. He has a track record of leading companies through periods of growth and expansion, with an emphasis on innovation and market penetration. Sakhavati's expertise lies in identifying and capitalizing on emerging trends in the healthcare industry, particularly in the areas of cannabis and pain management.
Track Record: Under Ali Sakhavati's leadership, Optima Medical Innovations Corp. has focused on expanding its product line and geographic reach. Key achievements include the rebranding of the company to Optima Medical Innovations Corp. and the establishment of a research agreement with Ryerson University. Strategic decisions have centered on diversifying revenue streams and strengthening the company's position in the Canadian and international markets.
TOKIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Optima Medical Innovations Corp. may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater risks compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier typically includes companies with limited operating history, distressed financials, or those that are unable to meet the listing requirements of higher exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing.
- Lack of transparency due to unknown disclosure status.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and audit reports.
- Confirm the identity and background of the company's management team.
- Assess the company's compliance with relevant regulations.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Consult with a qualified financial advisor before investing.
- Operation of multidisciplinary pain clinics.
- Research agreement with Ryerson University.
- Production and sale of CBD products in Canada and internationally.
- Company has been in operation since before November 2021 (when it changed its name).
- CEO has a background in healthcare and pharmaceuticals.
Optima Medical Innovations Corp. Healthcare Stock: Key Questions Answered
What does Optima Medical Innovations Corp. do?
Optima Medical Innovations Corp. operates in the healthcare sector, focusing on the production and sale of hemp-based cannabidiol (CBD) products and the operation of multidisciplinary pain clinics. The company offers a range of CBD products, including oils, capsules, topicals, and tinctures, which are sold in Canada and internationally. Additionally, the company's pain clinics provide comprehensive medical and interventional pain management services, physiotherapy, chiropractic care, and medical cannabis treatments, positioning it as a diversified player in the cannabis and pain management markets.
What are the main risks for TOKIF?
The main risks for Optima Medical Innovations Corp. include its negative profit margin and financial instability, intense competition from established pharmaceutical companies and other cannabis producers, changing regulations and legal restrictions on cannabis products, potential adverse health effects or negative publicity related to CBD use, and limited liquidity and transparency due to its OTC listing. These risks could negatively impact the company's financial performance, growth prospects, and stock price. Investors should carefully consider these risks before investing in TOKIF.
How does Optima Medical Innovations Corp. navigate regulatory approval processes?
Optima Medical Innovations Corp. operates in the heavily regulated cannabis and healthcare industries, requiring careful navigation of various regulatory approval processes. The company must comply with Health Canada regulations for the production, distribution, and sale of CBD products. Additionally, the operation of its multidisciplinary pain clinics is subject to provincial healthcare regulations and licensing requirements. The company's research agreement with Ryerson University may also involve regulatory oversight for clinical trials and new product development. Maintaining compliance with these regulations is critical for the company's operations and growth prospects.
What is Optima Medical Innovations Corp.'s strategy for expanding its pain clinic business?
Optima Medical Innovations Corp.'s strategy for expanding its pain clinic business involves a combination of organic growth and strategic partnerships. The company aims to increase patient volume at its existing clinics by offering a comprehensive range of pain management services, including medical and interventional treatments, physiotherapy, chiropractic care, and medical cannabis. Additionally, the company may seek to establish new clinics in underserved markets or partner with existing healthcare providers to expand its geographic reach. Leveraging telemedicine and virtual care technologies is also a key component of the company's expansion strategy.
What are the key factors to evaluate for TOKIF?
Evaluate TOKIF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does TOKIF data refresh on this page?
TOKIF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TOKIF's recent stock price performance?
Optima Medical Innovations Corp. (TOKIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product and service offerings (CBD products and pain clinics). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TOKIF overvalued or undervalued right now?
Valuing Optima Medical Innovations Corp. (TOKIF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market listing introduces additional risks and uncertainties.
- Analyst coverage is limited.